New Chinese patent approval for Episurf Medical

The Chinese patent office SIPO has announced that Episurf Medical (NASDAQ: EPIS B) has obtained another granted patent in China. The patent, entitled “Design method of a rig”, is within the area of individualised surgical instruments with a focus on the drill guide for the Episealer® Femoral Twin implant.

"The individualised drill guides form an important part of Episurf’s surgical instrument kit, to ensure optimal positioning of the Episealer® implants. This patent gives a stronger protection for the Episealer® Twin technology”, comments Katarina Flodström, CRO & Head of IP, Episurf Medical.

For more  information, please contact:
 

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14.30 CEST on 10 October 2018.

Tags: